Effect of sodium valproate administration on brain neprilysin expression and memory in rats. 2012

Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, United Kingdom. n.n.nalivaeva@leeds.ac.uk

Alzheimer's disease (AD) is accompanied by memory loss due to neuronal cell death caused by toxic amyloid β-peptide (Aβ) aggregates. In the healthy brain, a group of amyloid-degrading enzymes including neprilysin (NEP) maintain Aβ levels at physiologically low concentrations but, with age and under some pathological conditions, expression and activity of these enzymes decline predisposing to late-onset AD. Hence, up-regulation of NEP might be a viable strategy for prevention of Aβ accumulation and development of the disease. As we have recently shown, inhibitors of histone deacetylases, in particular, valproic acid (VA), were capable of up-regulating NEP expression and activity in human neuroblastoma SH-SY5Y cell lines characterised by very low levels of NEP. In the present study, analysing the effect of i.p. injections of VA to rats, we have observed up-regulation of expression and activity of NEP in rat brain structures, in particular, in the hippocampus. This effect was brain region- and age-specific. Administration of VA has also restored NEP activity and memory deficit in adult rats caused by prenatal hypoxia. This suggests that VA and more specific HDAC inhibitors can be considered as potential pharmaceutical agents for up-regulation of NEP activity and improvement of cognitive functions of ageing brain.

UI MeSH Term Description Entries
D008297 Male Males
D008568 Memory Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory.
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
September 2021, European journal of pharmacology,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
November 1985, Life sciences,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
April 2005, Brain research bulletin,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
January 1993, Neuropatologia polska,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
March 2017, Journal of clinical and diagnostic research : JCDR,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
January 2020, Iranian journal of medical sciences,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
January 1992, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
January 1988, Eksperimentalna meditsina i morfologiia,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
June 1984, Indian journal of experimental biology,
Natalia N Nalivaeva, and Nikolai D Belyaev, and David I Lewis, and Alasdair R Pickles, and Natalia Z Makova, and Daria I Bagrova, and Nadezhda M Dubrovskaya, and Svetlana A Plesneva, and Igor A Zhuravin, and Anthony J Turner
October 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies,
Copied contents to your clipboard!